Zucara Therapeutics has closed its US$25 million Series B financing, with contributions from T1D Fund and others, to advance its Phase 2a clinical trial for ZT-01.
Amount Raised
$25 Million
Round Type
Series B
TorontoBiotechnologyHealth CareTherapeuticsInvestors
Description
Zucara Therapeutics Inc. announced the completion of its US$25 million Series B financing, enabling the company to fund the remainder of its Phase 2a trial for ZT-01. The financing included investments from the T1D Fund and strategic participation from Sanofi. This funding supports the development of a once-weekly version of ZT-01, aimed at preventing hypoglycemia in diabetes patients
Quick answer
Zucara Therapeutics raised $25 Million in a Series B round, dated May 1, 2025. Investors: T1D Fund, The Perceptive Xontogeny Venture Fund and Sanofi. Zucara Therapeutics is based in Toronto, Ontario, Canada.
- How much did Zucara Therapeutics raise?
- Zucara Therapeutics raised $25 Million in a Series B round on May 1, 2025.
- Who invested in Zucara Therapeutics?
- T1D Fund, The Perceptive Xontogeny Venture Fund and Sanofi are named as investors in this round.
- What does Zucara Therapeutics do?
- Zucara Therapeutics, a CDRD and MaRS Innovation portfolio company, is developing the first drug therapy to prevent hypoglycemia in people with diabetes.
- Where is Zucara Therapeutics based and how big is it?
- Zucara Therapeutics is based in Toronto, Ontario, Canada. Fundz records about 10 employees.
- Who are the decision-makers at Zucara Therapeutics?
- Fundz holds 1 contact at Zucara Therapeutics, including the Co Founder & Chief Scientific Officer. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Zucara Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Arialys Therapeutics raised $15M on June 13, 2025.
- Canton Strategic Holdings, Inc. raised $2.5M (Seed) on June 13, 2025.
- ADC Therapeutics raised $100M (Private Equity) on June 12, 2025.
- Ensho Therapeutics raised $23M on June 12, 2025.
- Elkedonia raised $13M (Seed) on June 11, 2025.
- Mezzion Pharma raised $20M (Funding Round) on June 11, 2025.
Who to call at Zucara Therapeutics, and when
A new round usually means Zucara Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Zucara Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Zucara Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Zucara Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Zucara Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansZucara Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.